HopeVS Oncology is Excited to Offer Tanovea-CA1 For Our Lymphoma Patients

The U.S. Food and Drug Administration recently announced that it’s given conditional approval for  the first new animal drug to treat canine lymphoma. Also called lymphosarcoma, lymphoma is a type of cancer in dogs. The FDA said the active ingredient in Tanovea-CA1 is rabacfosadine, a substance that kills rapidly growing cancer cells.

Tanovea-CA1 must be prescribed by a licensed veterinarian because professional expertise is needed to correctly diagnose lymphoma in dogs, determine the best treatment, and manage potential side effects. Tanovea-CA1, which comes in a concentrated form, is diluted and given into a vein over 30 minutes. The infusion should be given by or under the supervision of a veterinarian experienced in chemotherapy.

 The “CA1” in Tanovea-CA1 means the drug is conditionally approved. Only animal drugs intended for minor species, such as ferrets or fish, or for minor uses in a major species, such as to treat certain types of cancer in dogs, are eligible for conditional approval. Tanovea-CA1’s conditional approval means that when used according to the label, the drug is safe and has a “reasonable expectation of effectiveness” for treating lymphoma in dogs.  

At HopeVS, our oncology service is excited to add this agent to our current list of drugs to treat lymphoma. We have been using this drug as part of clinical trials for the past several years and have treated well over 150 patients. If you have any questions regarding the drug or patients that may be eligible, please contact us.

Phone: 610 296-2099

Email: [email protected]


Posted in ,